Flora Peyvandi Introduces Breakthrough Protease-Resistant ADAMTS13 Enhancing VWF Regulation in Thrombotic Disorders
A new study published in Blood Advances by Prof. Flora Peyvandi and colleagues presents a study about a bioengineered, protease-resistant form of ADAMTS13, designed to enhance resistance to proteolytic degradation without compromising its functional regulation of von Willebrand factor (VWF)-posted on X:
“Mortality, diagnosis, and etiology of disseminated intravascular coagulation – A systematic review and meta-analysis: Communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.”
Recombinant ADAMTS13 has shown therapeutic potential in thrombotic disorders such as heritable TTP and is under investigation for use in acquired TTP and sickle cell disease. However, its susceptibility to degradation by proteases like plasmin limits its efficacy, especially under thrombo-inflammatory conditions. This study introduces protease-resistant ADAMTS13 variants—specifically modified in linker regions—that retain full VWF-cleaving function under flow. These stabilized forms resist cleavage by thrombin, FXIa, kallikrein, and neutrophil-derived enzymes, without compromising antithrombotic activity. The findings suggest that protease-resistant ADAMTS13 may enhance therapeutic durability in TTP and broaden its use in thrombosis-related diseases such as ischemic stroke and myocardial infarction.
Title: Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation
Autors: Veronica DeYoung, Rex Huang, Hasam Madarati, Rida Malik, Peter Andrisani, Cherie Teney, Colin A. Kretz
Similar exciting news can be found in Hemostasis Today.
-
Jun 7, 2025, 12:35WFH - The New Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual
-
Jun 7, 2025, 10:38Help Us Learn More About Hemophilia B - ATHN
-
Jun 7, 2025, 09:44New ICD-10-CM Codes For The Duffy Phenotype Have Recently Been Released - ASH
-
Jun 6, 2025, 17:16The Threshold for Children Receiving Blood Transfusion During Stem Cell Transplants Could Be Safely Reduced - BSH - Haematology
-
Jun 6, 2025, 09:57Cancer treatment and survivorship statistics, 2025 - A Cancer Journal for Clinicians
-
Jun 7, 2025, 10:28IL-10 From Tumoral B Cells Modulates the Diffuse Large B-Cell Lymphoma Microenvironment and Response to Immunotherapy
-
Jun 7, 2025, 08:46David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
-
Jun 6, 2025, 15:52Long-term Efficacy and Safety of Mitapivat in Non-Transfusion-Dependent α- or β-thalassaemia - British Journal of Haematology
-
Jun 6, 2025, 10:56Pip Nicolson Highlights Key PITT Case Insight on Anti-PF4 Antibody Testing
-
Jun 3, 2025, 15:30Effects of sickle trait on maternal and perinatal outcomes among pregnant women - Blood Vessels, Thrombosis & Hemostasis
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jun 7, 2025, 12:50ASH Sends a Letter to Senate Leaders Urging Them to Reject Harmful Medicaid Changes
-
Jun 7, 2025, 12:41ISTH - Abstracts for ISTH2025 are now LIVE
-
Jun 7, 2025, 12:29ASH - The Future of Classical Hematology is In Excellent Hands
-
Jun 7, 2025, 10:48Join Us For the Bleeding Disorders Conference 2025 - National Bleeding Disorders Foundation
-
Jun 6, 2025, 16:41RFP to Host the Annual EAHAD Congress 2029 is Now Open!